Updated on 8 October 2012
BioDiem's technology is also the basis for vaccines with a potentially lower side-effect profile as they are delivered into the nose with a spray or a dropper. This is easier to use in children and reduces the need for trained staff and reduces problems caused by injections.
An expanding business in the world's largest markets
BioDiem's license arrangement with the WHO under the Global Pandemic Influenza Action Plan for the public sector in developing nations has given BioDiem access to major developing markets such as India and China. We have partnered with the Serum Institute of India and Changchun BCHT Biotechnology Company (BCHT) in both these markets respectively. These networks are crucial for developers working in the developing world.
The Serum Institute of India (SII) now manufactures the swine flu pandemic vaccine, NasovacM, for the Indian market. The SII also holds a non-exclusive license for the private markets in Mexico, Argentina, Peru, South Africa, Bangladesh, Bhutan, Nepal, Pakistan and Sri Lanka. The SII's manufacturing facilities conform to WHO current good manufacturing practice (GMP) requirements and are approved by WHO/Geneva. The SII has also established itself as the world's largest producer of measles and DTP (diphtheria/tetanus/whooping cough) vaccines.
In 2011 the WHO sublicensed BioDiem's LAIV technology to a well-positioned Chinese biotech, BCHT. This license allows BioDiem to receive royalties from Chinese private sector market sales of seasonal and pandemic vaccines.
Our partnership with the WHO has been an essential part of our ability to navigate the complex environments represented by the health and regulatory systems of developing countries, and establishing these kinds of relationships is a case study for other companies attempting to enter developing markets.